Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

ClinicalTrials.gov ID: NCT03621670

Public ClinicalTrials.gov record NCT03621670. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT03621670
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,196 participants

Conditions and interventions

Interventions

  • Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ) Biological
  • Prevnar13 Biological
  • Pediarix Biological
  • Hiberix Biological
  • Rotarix Biological
  • M-M-R II Biological
  • Varivax Biological
  • Placebo (saline water) Biological
  • Prevnar 20 Biological

Biological

Eligibility (public fields only)

Age range
6 Weeks to 12 Weeks
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 26, 2018
Primary completion
Dec 26, 2024
Completion
Dec 26, 2024
Last update posted
Feb 9, 2026

2018 – 2024

United States locations

U.S. sites
56
U.S. states
24
U.S. cities
50
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205
GSK Investigational Site Fayetteville Arkansas 72703
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Anaheim California 92804
GSK Investigational Site Oakland California 94611
GSK Investigational Site Roseville California 95661
GSK Investigational Site Walnut Creek California 94596
GSK Investigational Site West Covina California 91790
GSK Investigational Site Lake Mary Florida 32746
GSK Investigational Site Miami Florida 33142
GSK Investigational Site Tampa Florida 33613
GSK Investigational Site Nampa Idaho 83686
GSK Investigational Site Nampa Idaho 83702
GSK Investigational Site Newton Kansas 67114
GSK Investigational Site Topeka Kansas 66604
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Louisville Kentucky 40202
GSK Investigational Site Louisville Kentucky 40207
GSK Investigational Site Louisville Kentucky 40291
GSK Investigational Site Baltimore Maryland 21021
GSK Investigational Site Fall River Massachusetts 02721
GSK Investigational Site Bingham Farms Michigan 48025
GSK Investigational Site Kansas City Missouri 64108
GSK Investigational Site Lincoln Nebraska 68516
GSK Investigational Site Omaha Nebraska 68128
GSK Investigational Site Liverpool New York 13090
GSK Investigational Site Syracuse New York 13210
GSK Investigational Site Boone North Carolina 28607
GSK Investigational Site Raleigh North Carolina 27609
GSK Investigational Site Cincinnati Ohio 45245
GSK Investigational Site Dayton Ohio 45406
GSK Investigational Site Dayton Ohio 45414
GSK Investigational Site Fairfield Ohio 45014
GSK Investigational Site South Euclid Ohio 44121
GSK Investigational Site Hermitage Pennsylvania 16148
GSK Investigational Site Pittsburgh Pennsylvania 15224
GSK Investigational Site Charleston South Carolina 29406
GSK Investigational Site Sioux Falls South Dakota 57105
GSK Investigational Site Clarksville Tennessee 37040
GSK Investigational Site Kingsport Tennessee 37660
GSK Investigational Site Beaumont Texas 77706
GSK Investigational Site Bryan Texas 77802
GSK Investigational Site Edinburg Texas 78504
GSK Investigational Site Houston Texas 77065
GSK Investigational Site Houston Texas 77090
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site San Antonio Texas 78244
GSK Investigational Site Layton Utah 84041
GSK Investigational Site Orem Utah 84057
GSK Investigational Site Provo Utah 84604
GSK Investigational Site Roy Utah 84067
GSK Investigational Site Salt Lake City Utah 84121
GSK Investigational Site Syracuse Utah 84075
GSK Investigational Site Richmond Virginia 23298
GSK Investigational Site Spokane Washington 99202
GSK Investigational Site Marshfield Wisconsin 54449

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03621670, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 9, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03621670 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →